Compare Axon Enterprise Inc (AXON) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs Cigna Corp — how do they compare? Axon Enterprise Inc trades at $601.88 (market cap $51.69B), while Cigna Corp trades at $275.55 (market cap $73.56B). The key difference: Cigna Corp is the larger of the two by market cap, and Cigna Corp pays a 2.24% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | CI | |
|---|---|---|
Market Cap | $51.69B | $73.56B |
Sector | Technology | Health |
52-Week High | $791.62 | $311.00 |
52-Week Low | $345.94 | $244.41 |
Enterprise Value | $52.83B | $98.27B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $616.97, up 3.46% in the last 24 hours, showing strong momentum with a bullish technical signal and consistent earnings beats. The stock is near its pivot point of $629, with support at $616 and resistance at $649. Revenue grew 35% year-over-year in Q2 2026, driven by AI and counter-drone offerings, though high valuation multiples like a P/E of 265.13 and P/S of 16.35 reflect premium pricing. Analyst consensus is strongly bullish with an $685 price target, but gross margin compression and elevated multiples pose risks.
Outlook remains positive given robust growth and AI adoption, but investors face valuation risks and margin pressures. The stock offers upside to consensus targets if execution continues, yet any growth slowdown could trigger significant multiple contraction. Key catalysts include Q3 2026 earnings and AI-driven contract expansions.
Cigna (CI) trades at $275.4, down 1.08% today, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, including a low P/E of 11.51 and consistent earnings beats, with Q2 2026 EPS of $7.78 exceeding expectations. Recent news highlights raised 2026 EPS guidance to at least $30.45, driven by growth in health services and insurance segments.
The outlook is positive, supported by analyst consensus with a $338.90 price target and 73.68% buy ratings. Key risks include competitive pressures and regulatory changes in healthcare. The valuation gap presents an opportunity, but investors should monitor medical cost trends and execution of growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
